This is the only entity in the advanced stages of a clinical trial that to date has been remarkably successful both from the safety standpoint and the improved vision results reported by the patients in the trial. This achievement combined with the potential of ACTC being the first company with a blood platelet solution circumventing the ethical issues surrounding embryonic stem cell research makes it entirely plausible (irrespective of shares outstanding) for ACTC to have a Market Cap of from $5-10 billion in the next two years. The impact of its successful science make it hard for me as a financial professional to think that this company that has struggled to stay alive and on the threshold of medical history will not be worth at least 1 to 2 % of Apple's current market cap. All that is required given what we know is time. The litigation issues will be settled as they have managements attention and this will be done with in early 2013. Thereafter, the ulitmate investment realization will be the reward for the believers.
Hey fact, it sure is gona be nice holding lots of shares when this baby finally takes off. Im betting a market cap of 1 billion by end of year, and 100 billion in 5 years if we get thru trials without loosing to much of whats on the table to partners. Steve